Technology
Health
Biotechnology

Organovo

$0.5001
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0796 (-14.62%) Today
+$0.0351 (7.55%) After Hours

Why Robinhood?

You can buy or sell Organovo and other stocks, options, ETFs, and crypto commission-free!

About

Organovo Holdings, Inc. Common Stock, also called Organovo, is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. Read More It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo Holdings was founded on January 30, 2012 and is headquartered in San Diego, CA.

Employees
75
Headquarters
San Diego, California
Founded
2012
Market Cap
54.76M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
688.19K
High Today
$0.465
Low Today
$0.3701
Open Price
$0.45
Volume
4.49M
52 Week High
$1.97
52 Week Low
$0.3701

Collections

Technology
Health
Biotechnology
Medical
Pharmaceutical
US
North America

News

Seeking AlphaMay 23

Organovo Holdings, Inc. CEO Taylor Crouch on Q4 2019 Results - Earnings Call Transcript

Organovo Holdings, Inc. (NASDAQ:ONVO) Q4 2019 Earnings Conference Call May 22, 2019 5:00 PM ET Company Participants Steve Kunszabo - Investor Relations Taylor Crouch - CEO Craig Kussman - CFO Conference Call Participants Ed Arce - H.C. Wainwright Matthew Cross - JonesTrading Operator Good day, and welcome to Organovo Holdings, Inc. Fiscal Fourth Quarter 2019 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note, this event is being recorded. I ...

439
Seeking AlphaMay 22

Organovo down 11% after hours on tepid FQ4 results, extended timeline for liver tissue patch

Micro cap Organovo (NASDAQ:ONVO) is off 11% after hours in reaction to its preliminary fiscal Q4 results. Highlights: Revenue was $0.7M (-38%), net loss was ($7.0M). Cash and equivalents totaled $36.5M at the end of March. Current resources plus the continued use of its at-the-market stock sales facility should be sufficient to fund operations into calendar 2021. Citing the need for additional preclinical studies, additional work to optimize the manufacturing process and the need for more data to support...

524
Yahoo FinanceApr 26

The Organovo Holdings (NASDAQ:ONVO) Share Price Is Down 83% So Some Shareholders Are Rather Upset

Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Anyone who held Organovo Holdings, Inc. (NASDAQ:ONVO) for five years would be nursing their metaphorical wounds since the share price dropped 83% in that time. And some of the more recent buyers are probably worried, too, with the stock falling 21% in the last year. Unhappily, the share price slid 2.2% in the last week. While a drop like that is definitely a body blow, money isn't as important as health and happiness. See our...

1,601

Earnings

-$0.10
-$0.08
-$0.07
-$0.05
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
-$0.06 per share
Actual
Expected May 30
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.